A 6-Week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-Dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension

Trial Profile

A 6-Week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-Dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2009

At a glance

  • Drugs Valsartan; Valsartan/hydrochlorothiazide
  • Indications Hypertension
  • Focus Biomarker; Therapeutic Use
  • Acronyms VELOCITY
  • Most Recent Events

    • 05 Nov 2009 Primary endpoint 'Systolic blood pressure' has been met according to results published in the Journal of Human Hypertension.
    • 20 Dec 2006 Status change
    • 30 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top